We tested the in vitro and in vivo anti-tumor activity of the maytansinoid DM1, a potent antimicrotubule agent, covalently linked to the murine monoclonal antibody (mAb) B-B4 targeting syndecan-1 (CD138). We evaluated the in vitro activity of B-B4-DM1 against a panel of CD138 
Introduction
Following the discovery of monoclonal antibody (mAb) technology 1 , numerous attempts have been made to utilize mAbs targeted to cancer-associated antigens for the treatment of human
cancer. Of many mAbs tested, several were found to be therapeutically active, either as naked antibodies or as immunoconjugates of radionuclides [2] [3] [4] . Conjugates of antibodies with cytotoxic agents have also been explored as anti-cancer agents 2,3 as a means of improving the selectivity of cytotoxic drugs by targeting them to antigens preferentially expressed on the surface of malignant cells. Mylotarg, a conjugate of anti-CD33 humanized monoclonal antibody with a highly cytotoxic DNA-damaging agent calicheamicin, has recently been approved by the FDA as the first drug of this type for clinical treatment of myeloid leukemia [5] [6] [7] .
Immunoconjugates of the highly potent cytotoxic drug maytansine derivative DM1 (N -(3-mercapto-1-oxopropyl)-maytansine) are also being evaluated as antigen-targeted anti-cancer agents 8 . Maytansine 9 is a natural product originally derived from the Ethiopian shrub
Maytenus serrata. This drug inhibits tubulin polymerization [9] [10] [11] , resulting in mitotic block and cell death. The cytotoxicity of maytansine is 200-1,000-fold higher than that of anti-cancer drugs in clinical use that affect tubulin polymerization, such as Vinca alkaloids or taxol. However, clinical trials of maytansine indicated that it lacked a therapeutic window, due to high systemic toxicity.
DM1 is 3-to 10-fold more cytotoxic than maytansine, and can be converted into a prodrug by linking it via disulfide bond to a mAb directed against a tumor-associated antigen. Such a conjugate (tumor activated prodrug or TAP) is not cytotoxic in the blood compartment, since it is activated only upon binding to target cells, with subsequent release of the drug 12 . Several mAb-DM1
conjugates have been developed 13 , and to date huC242-DM1 and huN901-DM1 have been evaluated in clinical trials. These conjugates were well tolerated, did not induce any detectable immune response, and had a long circulation time [14] [15] [16] .
The murine IgG1 mAb B-B4 binds to a linear epitope between residues 90-95 of the core protein on human syndecan-1 (CD138), a member of the family of transmembrane heparan sulfate
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From proteoglycans 17, 18 . This antigen was originally described as a membrane proteoglycan present on cells of epithelial origin, and was subsequently found on hematopoietic cells 19 . In the normal human hematopoietic compartment, CD138 expression is restricted to plasma cells 17, 20 ; in particular, CD34 + stem and progenitor cells do not express CD138 17 . In malignant hematopoiesis, CD138 is highly expressed on the majority of multiple myeloma (MM) cells, many Hodgkin's lymphomas with classic Reed-Sternberg cells 17, 20 , as well as a fraction of chronic lymphocytic leukemia (B-CLL) 21 , acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML) 22, 23 cells. At present, CD138 is a promising antigen for targeting MM cells. However, the lack of human CD138 on mouse tissues limits pre-clinical evaluation of the safety of mAbs targeting this antigen.
Here we report our preclinical study of B-B4-DM1 as a novel treatment for MM. We evaluated the in vitro activity of B-B4-DM1 against a panel of CD138 + and CD138 -cell lines, as well as patient MM cells adherent to bone marrow stroma cells (BMSCs). We further examined the anti-tumor potency of B-B4-DM1 using three in vivo models of human MM in SCID mice.
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Materials and Methods

Preparation of mAb-DM1 conjugate
The thiol-containing maytansinoid DM1 was synthesized from the microbial fermentation product ansamitocin P-3, as previously described 8 . Characterization of murine B-B4 17 and preparation of humanized mAb C242 (huC242) 24 have been previously described. MAb-drug conjugates were prepared as described elsewhere 25 . An average of 3.5 DM1 molecules were linked per antibody molecule. Activity of a DM1-conjugate against MM cells has been recently demonstrated 26 . human genes, and GeneChip(r) arrays were scanned on a GeneArray(r) Scanner (Affymetrix, Inc., Santa Clara, CA).
Cell lines and patient cells
Microarray Data Analysis
Normalization of arrays and calculation of expression values was performed using the DNA-Chip Analyzer (dChip) program. Arrays were normalized based on relative signal produced for an invariant subset of genes. This model-based method was used for probe selection and computing expression values. By pooling hybridization information across multiple arrays, it is possible to assess standard errors for the expression level indexes. This approach also allows automatic probe selection in the analysis stage to reduce errors due to cross-hybridizing probes and image contamination.
Immunohistochemistry
Paraffin multi-tissue arrays were purchased from Biochain Institute (Cat. No. T8234708, Lot A603500) and Zymed Labs, "Maxarrays". Normal frozen organ tissues were cut into 5 µm-sections and fixed in cold 2% paraformaldehyde/PBS prior to staining, which was performed using the ABC peroxidase technique.
Colorimetric survival assay
Cell survival was examined using a tetrazolium colorimetric assay (CellTiter 96 ® Non-Radioactive
Cell Proliferation Assay; Promega, WI), as previously described 27 . Cells SCID-hu mouse model. Human fetal long bone grafts were implanted into SCID mice (SCID-hu mice) as previously described [29] [30] [31] [32] [33] [34] [35] [36] . Approximately 8 weeks following bone implantation, 2 to 5 x 10 6 BM cells from a MM patient in 50 µl PBS were injected directly into human bone of SCID-hu hosts. Production of human paraprotein in mouse serum was monitored as an indicator of myeloma engraftment and growth. At least 2 consecutive measurements of increasing levels of circulating human immunoglobulin (huIg) signified human MM cell growth.
Cell proliferation Assay
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Measurement of serum paraprotein concentration
Blood (50-100 µl) was withdrawn from the tail vein for measurement of human paraprotein in murine serum using ELISA (Bethyl, Montgomery, TX). Goat anti-human and antisera were used for capture and goat anti-human or HRP conjugates were used for detection.
Statistical analysis
Statistical significance of differences was determined using Student's t-test. Differences were considered significant when p<0.05. (Fig. 1F ). Taken together, these results indicate that CD138 is expressed at high density in a majority of MM patients.
Distribution of CD138 antigen in normal human tissues
We next evaluated the reactivity of mAb B-B4 on a large panel of human tissues by immunohistochemistry (IHC). Freshly frozen tissue sections and paraffin multi-tissue arrays were analyzed, in conjunction with assay controls OPM2 and Namalwa cell sections, using the ABC immunoperoxidase method. The slide evaluation employed a four-tiered scoring system and included the staining intensity (scored 0, 1, 2 or 3), uniformity (scattered, focal, heterogeneous or homogeneous), site of reactivity (structure), and main type of reactive cell in test samples ( therefore, paraffin-embedded liver sections were evaluated. In the paraffin-embedded liver sections, we observed less variation within cell constituents: no staining of hepatocytes was observed, with moderate to strong staining in spaces between the hepatocytes, or sinusoidal lining cells, and stronger staining of hepatic vein. Strong staining was seen in three kidney samples, specifically in tubules in the cortex distal to the main blood supply, and in the medullary region of one sample.
The glomeruli present in these samples showed no B-B4 staining.
We also tested whether mAb B-B4 is reactive towards cynomolgus monkey CD138. If it is then the monkey could be used for pre-clinical evaluation of CD138-related systemic toxicity of B-B4-DM1. There was virtually no staining in any of the normal monkey tissues examined, including colon, epidermis, and kidney tubules. These data indicated that mAb B-B4 does not react with cynomolgus CD138.
B-B4-DM1 is selectively cytotoxic to CD138 + MM cell lines in vitro
To 
inhibitory activity of the immunoconjugate is specifically related to the mAb-delivered drug, we similarly tested the effect of equimolar concentrations of B-B4 antibody or unconjugated drug DM1. Even at the highest tested concentrations (5 µg/ml or 31 nM), B-B4 did not affect the growth of cells following a 96 h exposure ( Fig. 2A) , whereas free DM1 was equally and highly cytotoxic in both CD138
+ and CD138 -cell lines (Fig. 2C) . These data indicate that the activity of the immunoconjugate is related to neither the differential sensitivity of cells to the drug, nor the intrinsic properties of the antibody.
B-B4-DM1 is cytotoxic to CD138 + MM cell lines and patient MM cells adherent to BMSCs
Since adhesion of MM cells to BMSCs induces development of drug resistance in MM cells 41 
CD138
+ cells exposed to B-B4-DM1 and free DM1, whereas no significant differences were detected in cells treated with unconjugated mAb alone. We next analyzed cell cycle changes induced by an exposure of MM cells to B-B4-DM1. Cells were treated with the immunoconjugate for 48 h, labeled with PI, and analyzed using flow cytometry. As shown in Fig. 4B , B-B4 mAb alone had no significant effect on the proportion of cells in G2/M phase compared to untreated cells (15% vs 16%), whereas exposure of MM cells to B-B4-DM1 resulted in accumulation of the majority (89%) of cells in G2/M.
B-B4-DM1 inhibits tumor growth in a human MM xenograft model in SCID mice
We first used a human MM s.c. xenograft model in SCID mice to study the in vivo activity of B-B4-DM1 against CD138 + OPM1 cells. In this model, the therapeutic efficacy of B-B4-DM1 was measured in mice bearing large palpable tumors (average size 453±74 mm 3 ). Animals were treated daily i.v. for 3 consecutive days with either vehicle alone (PBS; n = 5), unconjugated B-B4 (13.3 µg/kg; n=5), B-B4-DM1 (150 µg DM1/kg; n =5), or control huC242-DM1 (150 µg DM1/kg; n =5) which does not bind OPM1 cells. Tumor size and overall survival were monitored in these cohorts.
As shown in Fig. 5A 
B-B4-DM1 inhibits MM growth in SCID-hu hosts
Since the SCID-hu model of MM mimics the pathological behavior of the disease 36 , we next studied the efficacy of B-B4-DM1 treatment in SCID-hu mice injected with patient MM cells. In these experiments we studied the activity of the immunoconjugate on disease confined to the human fetal bone chip implanted s.c. in mice. Four SCID-hu mice were injected with patient MM cells (IgG ), and tumor growth in the human bone environment was reflected by increasing serum chain levels. Mice were treated with either B-B4-DM1 (150 µg DM1/kg) or control huC242-DM1
(150 µg DM1/kg) for 3 consecutive days. As seen in Fig. 7A and B, treatment with B-B4-DM1
induced a significant reduction of chain, whereas the human paraprotein continued to rise in mice treated with control antibody. These results confirm activity of B-B4-DM1 as an anti-tumor agent in SCID-hu models of human MM. CD138 expression on MM cells was significantly higher than that on normal plasma cells. In non-hematopoietic compartments, syndecan-1 had been previously reported to be expressed on epithelia of many organs and weakly expressed on endothelial cells 48, 52 . We therefore undertook an extensive IHC, using paraffin slides and frozen sections, of multiple independent tissue samples from critical organs. We found that CD138 expression is restricted in normal tissues. Tissues staining with B-B4 included colon and esophagial surface epithelium, ductal breast epithelium, skin epidermis, and renal tubules. Due to the lack of reactivity of B-B4 with murine or cynomolgus monkey CD138, the issue of its systemic toxicity cannot be addressed in these models. B-B4-DM1 toxicity in humans can therefore only be examined in a dose-escalation phase-I clinical trial.
Several mAbs directed against epithelial antigens have been used in vivo to target malignancies of epithelial origin, and uptake of these antibodies by the tumors was higher than that by normal epithelia [53] [54] [55] , indicating that target cell accessibility 56 may vary in normal versus neoplastic tissues.
In a clonogenic assay, a B-B4 immunotoxin was not effective in killing the CD138+ HepG2 hepatocyte cell line or normal endothelial cells, but was potent against the MM cell line RPMI8226 48 .
Early attempts at using mAbs to deliver conventional cytotoxic drugs were not successful, likely due to the low inherent cytotoxic potency of these drugs 57 . Recently, a new generation of antibody-drug conjugates have been developed, which employ highly cytotoxic small drugs that are 100-to 1000-fold more potent than conventional chemotherapeutic agents 57 . The FDA-approval of Mylotarg, the first antibody-drug conjugate of this type, has led to a resurgence of interest in developing mAb-based cancer treatments. The use of mAbs conjugated to another highly potent cytotoxic drug, the maytansine derivative DM1 used in this study, has the advantage of significant cytotoxic activity and limited systemic toxicity. Recently, immunoconjugates of DM1 with huC242
(huC242-DM1) 25, 58 or huN901 (huN901-DM1), reactive against a glycotope on MUC1 and against CD56 (NCAM) respectively, have been evaluated in phase I clinical studies [14] [15] [16] in cancer patients.
Both immunoconjugates showed biological activity and limited side effects. These studies provide For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From Table 1 . Immunolocalization/distribution of B-B4 in human normal tissues B-B4, or the control murine IgG1, was used at a concentration of 0.1 µg/ml and 2.5 µg/ml on frozen sections or on paraffin arrays respectively, to achieve equivalent staining in controls.
Score Key:
Staining intensity: 3 = strong, 2 = moderate, 1 = weak, 0 = no staining homo (homogeneous) = > 75 % of cells stained hetero (heterogeneous) = 25-75 % of cells stained focal = < 25 % of cells stained scattered = < 5 % cells stained Symbol/Abbreviation: * = Corrected for the control sample treated similarly with the non-specific antibody ND = Not done, CTN= control.
